Category | Advanced therapy
Decades of work and new understanding transformed cell and gene therapies (CGTs) from a hyped-up possibility to a life-changing reality for many patients. CGTs represent a growing market in the United States and other regions of the world, with multiple new global approvals expected within the next few years. However, patient challenges and operating model complexities threaten realization of the CGT promise and require innovators and partners to find ways to streamline the clinical and patient journeys.
Patients should be at the epicenter of all thinking when it comes to drug development and delivery. Patient centricity distills all the complexities of the industry into a single focus: to improve the life of each individual and optimize their experience with their condition and treatment. Patient mapping allows developers to understand the steps of the patient journey and the touchpoints that provide opportunities for improvements. The current journey for patients who could benefit from CGTs is quite complex (see Figure 1). Our discussions with developers, patient advocacy groups, and other key stakeholders have elucidated a nonlinear process that involves multiple touchpoints and procedures, varied service providers, and numerous locations. In addition, the caregiver is an important stakeholder in the patient journey, yet their role is often fraught with anxiety, frustration, and confusion. These factors have resulted in a complex CGT clinical value journey that can lead to missed opportunities for optimal care.
As we better appreciate patients’ pain points in their CGT journey, we can find ways to streamline and improve our overall operating model (see Figure 2).
Following are a few examples of ways Thermo Fisher Scientific strives to influence and streamline the operating model for complex CGT delivery:
The CGT space represents a very complex ecosystem and requires a high level of collaboration and communication among many relevant parties if patient centricity is to be maintained. Through years of listening to and working with various stakeholders in the field, Thermo Fisher understands the best ways to support partners who are not only developing but also delivering CGTs to patients. We offer a unique combination of end-to-end solutions for CGT development, manufacturing, and distribution. By their very nature, the processes associated with CGT are labor intensive and costly, but our innovative solutions and focus on practicality and efficiency can optimize value for both customers and patients.